Century Therapeutics (IPSC) Gains from Sales and Divestitures (2021 - 2026)
Century Therapeutics (IPSC) reported Gains from Sales and Divestitures of $441965.0 for Q1 2026, down 8.72% year-over-year from $484190.0 in Q1 2025, and up 1680.61% quarter-over-quarter from $24821.0 in Q4 2025.
Century Therapeutics (IPSC) Gains from Sales and Divestitures (2021 - 2026) Analysis & Trends
Century Therapeutics (IPSC) has 6 years of Gains from Sales and Divestitures data on file, last reported at $441965.0 in Q1 2026.
- Gains from Sales and Divestitures for Q1 2026 came in at $441965.0, down 8.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $441965.0 (down 8.72% YoY), and the FY2025 annual result was $24821.0, down 98.34% from the prior year.
- Gains from Sales and Divestitures grew to $441965.0 in Q1 2026 per IPSC's latest filing, from $24821.0 in the prior quarter.
- Over five years, Gains from Sales and Divestitures peaked at $1.5 million in Q4 2024 and troughed at $24685.0 in Q1 2024.
- A 5-year average of $279124.2 and a median of $95877.0 in 2023 frame the typical range for Gains from Sales and Divestitures.
- On a YoY basis, Gains from Sales and Divestitures climbed as much as 1861.47% in 2025 and fell as far as 98.34% in 2025.
- A 5-year view of Gains from Sales and Divestitures shows it stood at $488758.0 in 2022, then sank by 80.38% to $95877.0 in 2023, then surged by 1461.5% to $1.5 million in 2024, then tumbled by 98.34% to $24821.0 in 2025, then surged by 1680.61% to $441965.0 in 2026.
- Business Quant data shows IPSC's Gains from Sales and Divestitures at $441965.0 in Q1 2026, $24821.0 in Q4 2025, and $433168.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Century Therapeutics | 444.99 Mn | 444.99 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 441,965.00 |
| Mar 31, 2026 | 441,965.00 |
| Dec 31, 2025 | 24,821.00 |
| Dec 31, 2025 | 24,821.00 |
| Sep 30, 2025 | 433,168.00 |
| Sep 30, 2025 | 433,168.00 |
| Jun 30, 2025 | 24,734.00 |
| Jun 30, 2025 | 24,734.00 |
| Mar 31, 2025 | 484,190.00 |
| Mar 31, 2025 | 484,190.00 |
| Dec 31, 2024 | 1.50 Mn |
| Dec 31, 2024 | 1.50 Mn |
| Sep 30, 2024 | 24,731.00 |
| Sep 30, 2024 | 24,731.00 |
| Jun 30, 2024 | 24,685.00 |
| Jun 30, 2024 | 24,685.00 |
| Mar 31, 2024 | 24,685.00 |
| Mar 31, 2024 | 24,685.00 |
| Dec 31, 2023 | 95,877.00 |
| Dec 31, 2023 | 95,877.00 |